|Videos|January 8, 2021
C. Difficile Treatment: Bezlotoxumab
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.